Dermatological Drugs - Asia

Asia

In 2024, the revenue in the Dermatological Drugs market in Asia is projected to reach €4.05bn.
It is expected to show an annual growth rate (CAGR 2024-2029) of 6.23%, resulting in a market volume of €5.48bn by 2029.
When compared globally, United States is expected to generate the highest revenue, amounting to €10,820.00m in 2024.
In Japan, the demand for dermatological drugs is driven by a strong emphasis on skincare and a high prevalence of skin conditions among the population.

Key regions: United Kingdom, Canada, Japan, Europe, China

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The demand for dermatological drugs in Asia has been steadily increasing over the years.

Customer preferences: Consumers in Asia are becoming increasingly conscious about their appearance and are willing to spend more on skincare products. The rise of social media platforms has also led to a greater emphasis on physical appearance, leading to an increased demand for dermatological drugs.

Trends in the market: South Korea has emerged as a major player in the dermatological drugs market, with a focus on innovative products such as BB creams and sheet masks. Japan has also seen a rise in demand for dermatological drugs, particularly for anti-aging products. In China, the market is dominated by local brands, with a focus on traditional Chinese medicine-based products. India has seen a surge in demand for dermatological drugs due to the increasing prevalence of skin diseases and disorders.

Local special circumstances: In South Korea, the popularity of K-beauty has led to a surge in demand for dermatological drugs, with consumers seeking out innovative and effective products. In Japan, the aging population has led to a greater demand for anti-aging products. In China, the market is heavily regulated, with strict requirements for product registration and approval. In India, the prevalence of skin diseases such as acne and eczema has led to a greater demand for dermatological drugs.

Underlying macroeconomic factors: The growing middle class in Asia has led to an increase in disposable income, which has in turn led to a greater demand for skincare products. The rise of e-commerce platforms has also made it easier for consumers to access a wider range of dermatological drugs. Additionally, the increasing prevalence of skin diseases and disorders has led to a greater need for effective treatments, driving demand for dermatological drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.